Is the CSL share price heading to $345? This analyst thinks so

Let's see why one analysts is tipping this high-quality stock to outperform.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The CSL Ltd (ASX: CSL) share price has languished in 2024 while the market has flourished.

During the period, the biotechnology giant's shares have lost approximately 3% of their value.

This compares unfavourably to the performance of the ASX 200 index, which is up over 10% year to date. And that excludes the dividends paid over the period, which add somewhere in the region of 4%.

Perhaps the most disappointing part of this is that over the past couple of decades, the CSL share price has built a reputation of being a market-beater.

But we just simply have not seen this since the pandemic for a number of reasons. Since late 2019, CSL's shares have gone sideways.

But those lost years could be a thing of the past in the near future with analysts tipping CSL to find its way again.

A group of men in the office celebrate after winning big.

Image source: Getty Images

CSL share price tipped to rise strongly

According to a recent note out of Bell Potter, its analysts believe that the company is about to embark on a journey of strong and consistent growth.

In light of this, its analysts feel that the CSL share price is now being undervalued by the market.

Commenting on why it thinks now could be a good time to invest in the company, the broker said:

CSL presents an attractive buying opportunity as we anticipate the start of a margin recovery phase for CSL, driving above-market earnings growth over the next few years. CSL trades at a 12-month forward PE of ~28x, representing a discount to its 10-year average of ~31x. Furthermore, the company will continue to deleverage the balance sheet over the next few years. Given the company's proven quality and growth prospects, we believe significant upside remains.

In our view the stock looks undervalued on a PE ratio 18%/8% below 5yr/10yr historical averages and is set for double-digit earnings growth driven by the core Behring division.

The note reveals that Bell Potter has a buy rating and $345.00 price target on CSL's shares. Based on its current share price of $280.74, this implies potential upside of almost 17% for investors over the next 12 months.

To put this into context, a $5,000 investment in the company would turn into approximately $5,800 by this time next year if Bell Potter is on the money with its recommendation.

Overall, this could make CSL a great option for investors that are wanting to add some high-quality stocks to their portfolio for 2025.

Motley Fool contributor James Mickleboro has positions in CSL. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Group of doctors celebrate by pumping fists in the air
Healthcare Shares

Healthcare shares led the ASX 200 last week. Is a sector comeback underway?

ASX 200 healthcare shares are down 39% over 12 months, but have lifted 13% since 3 June.

Read more »

A doctor appears shocked as he looks through binoculars on a blue background.
Healthcare Shares

If I invest $8,000 in CSL shares, how much passive income will I receive in 2027?

This business could deliver healthy payouts in the next few years…

Read more »

Surgeon looking at a monitor in an operating room.
Healthcare Shares

The bull and bear case for CSL shares

What are the realistic prospects for this once powerful healthcare company?

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Healthcare Shares

Why this red-hot ASX healthcare share keeps climbing

A 1,600% gain hasn't slowed this stock down.

Read more »

A woman smiles at the outlook she sees through binoculars.
Healthcare Shares

How much could the CSL share price rise in the next year?

Can this business deliver very healthy gains from here?

Read more »

Group of scientists cheering in the lab after the company received good news.
Healthcare Shares

Why is this ASX biotech stock blasting higher today?

Investors are backing the biotech's growing commercial and pipeline potential.

Read more »

Modern accountant woman in a light business suit in modern green office with documents and laptop.
Healthcare Shares

Down 30%, should I buy ResMed shares now?

A sharp fall can make investors cautious, but it can also create opportunity when the long-term business remains strong.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

3 beaten-down ASX healthcare shares tipped to rise up to 202%

Analysts have a strong buy rating on two of these healthcare stocks, and all three are tipped to have an…

Read more »